Clinical Trial Update: Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating alternating VA and low-dose CHA regimens for unfit, newly diagnosed acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Low-dose CHA regimen
• VA regimen

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 2 | Status: RECRUITING